Prologue Medicines

Executive Summary

Prologue Medicines is a private biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company leverages its proprietary DELVE platform to systematically mine the viral proteome, identifying viral proteins that have evolved to modulate human physiology. This approach aims to unlock a vast, untapped source of potential therapeutics, generating programmable medicines that can address a broad range of diseases. By combining computational methods and next-generation sequencing, Prologue can rapidly decode and engineer viral proteins into drug candidates, positioning itself at the forefront of viral-inspired drug discovery.

Upcoming Catalysts (preview)

• Q3 2026Platform partnership or licensing deal40% success
• Q4 2026Lead candidate nomination for a preclinical program50% success
• Q2 2026Series A or seed extension financing60% success